AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00810342 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physical activity tailored
Description: tailored telephone counseling, email feedback, and website resources over 12 months
Study NCT00810342 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: physical activity standard
Description: standard print and website information on how to become more active
Study NCT03659383 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Optimal hypoglycemic treatment
Description: Standardize oral hypoglycemic medication and adjust insulin dose according to blood glucose values obtained by self-monitoring
Study NCT01903993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Participants received atezolizumab of 1200 mg (equivalent to an average body weight-based dose of 15 milligram per kilogram \[mg/kg\]) which was administered by IV infusion q3w on Day 1 of each 21 day cycle. Participants were allowed to continue treatment beyond progression per response evaluation criteria in solid tumors (RECIST) v1.1 if they were experiencing clinical benefit per investigator, did not have a decline in performance status, did not have signs or symptoms of unequivocal progression, did not have tumor progression at critical sites, and signed an informed consent signature page acknowledging deferment any standard treatment options that may exist in favor of continuing atezolizumab.
Study NCT03739580 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DCB angioplasty (Orchid, Acotec Scientific Co. Ltd.)
Description: for popliteal stenosis/occlusive lesions, randomised received DCB or Stent deployment.
Study NCT03739580 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stent (Maris,Medtronic.USA or Sinus/Supera, Germany)
Description: for popliteal stenosis/occlusive lesions, randomised received DCB or Stent deployment.
Study NCT01793077 — intervention group
Intervention type: DRUG
Intervention: Depo-Eligard®
Description: Subcutaneous
Study NCT01447199 — intervention group
Intervention type: BEHAVIORAL
Intervention: Health and Diet Questionnaire
Description: Mailed questionnaires asking about foods eaten, cooking methods as well as overall health, and vitamin/medication use, taking several hours to complete.
Study NCT00755456 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PD solution containing glucose
Description: Instillation of PD solutions containing Glucose (1.5 or 2.5%, w/v) for the diurnal exchanges, and 1 PD solution containing icodextrin (7.5 w/v) for nocturnal exchange. PD solutions are instilled for 120 days.
Study NCT00755456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD solution containing glucose and L-carnitine
Description: Instillation of PD solutions containing Glucose (1.5 or 2.5%, w/v) and L-carnitine (0.1%, w/v) for the diurnal exchanges, and 1 PD solution containing icodextrin (7.5 w/v) for nocturnal exchanges. PD solutions are instilled for 120 days.
Study NCT01918371 — intervention group
Intervention type: DRUG
Intervention: Anti-VEGF
Description: Patients with retinal vein occlusion or diabetic macular edema receiving anti-VEGF injection(s) in accordance with standard of care practices. This is a retrospective chart review study.
Study NCT01382862 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stroke Emergency Mobile Unit (STEMO)
Description: Patients treated in the STEMO may receive a CT-scan and point-of-care laboratory work up. This depends on the results of the neurological examination including assessment of medical history and the indication for scanning by the radiologist on call. In case of no contraindications patients with acute ischemic stroke will receive intravenous tissue Plasminogen Activator (0.9 mg/kg BW) according to the routine use of tissue Plasminogen Activator in Germany within 4.5 hours of symptom onset but with no formal upper age limit. (In other words, patients older than 80 years will not be excluded.) In case of increased INR and intracerebral hemorrhage patients will receive Prothrombin Complex Concentrate (PCC). All other indications will be treated according to national guidelines or as considered appropriate by the neurologist.
Study NCT00243022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Boswellia serrata extract
Description: given orally
Study NCT00243022 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cyanocobalamin
Description: given orally
Study NCT00243022 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: cyanocobalamin
Description: given orally
Study NCT02787447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TKI
Description: Gefitinib 250mg po qd or Erlotinib 150mg po qd or Icotinib 125mg po tid
Study NCT02787447 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Thoracic Hypofractionated Radiotherapy
Description: 40-45 Gy/5-15f
Study NCT02787447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymosin Alpha 1
Description: Initiating thymosin alpha 1 therapy(1.6mg, qd, d1-d14;1.6mg, biw, d15-d90) at the second week of radiotherapy.
Study NCT02126462 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Na-APR-1 (M74)/Alhydrogel®
Study NCT02126462 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Na-GST-1/Alhydrogel®
Study NCT02126462 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hepatitis B vaccine
Description: Hepatitis B vaccine co-administered with saline
Study NCT02782611 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ENHANCE: Enduring Happiness and Continued Self-Enhancement
Description: ENHANCE is a skill-based intervention to teach people a wide variety of strategies that have been shown to boost happiness. Each session of ENHANCE follows a similar format targeted to address three central goals. First, in each session, participants will complete an active learning module designed to educate participants about one of the ten overarching topics featured in this program (e.g., goals, close relationships). Next, participants will engage in activities that put these principles into practice. Finally, this program is designed to encourage a skill-building mindset by helping participants develop habits to integrate these principles into maintained activity in their daily lives moving forward.
Study NCT01140282 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: questionnaire administration
Description: Administered within 3 days of baseline testing and at post-trial visit
Study NCT05047484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN2050
Description: Powder-in-capsule (PIC).
Study NCT05047484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: PIC.
Study NCT00700050 — intervention group
Intervention type: DRUG
Intervention: Hypertonic saline
Description: Subjects will be asked to expectorate sputum samples. If necessary to achieve this, subjects will inhale wet-nebulized 3% saline for up to 7 minutes each for up to 3 cycles.
Study NCT03202732 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: DiabetesFlex
Description: DiabetesFlex consist of one mandatory and two optional consultations. Before the consultations patients receive the AmbuFlex Diabetes questionnaire.~The AmbuFlex Diabetes questionnaire is based on both validated questionnaires and clinical consensus. The AmbuFlex Diabetes questionnaire consists of: SF36 well-being question, WHO-5 Well-being Index. Questions concerning: HgA1c, home-based blood pressure monitoring, incidents of hypoglycemia, diabetes complications, regular eye check, regular food check, erectile dysfunction and peripheral neuropathy, The PAID scale, Topics patients may want to talk with the health care professional about, the patient's evaluation of the need for diabetes care. View the AmbuFlex Diabetes questionnaire at the homepage: www.diabetesflex.auh.dk.
Study NCT02028962 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle counseling
Study NCT04121767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edoxaban
Description: oral edoxaban 60mg once daily for 3 months
Study NCT01140282 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Administered within 3 days of baseline testing and at post-trial visit
Study NCT01140282 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: quality-of-life assessment
Description: Administered within 3 days of baseline testing and at post-trial visit
Study NCT01140282 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Administered within 3 days of baseline testing and at post-trial visit
Study NCT01140282 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: management of therapy complications
Description: Assessed within 3 days of baseline testing and at post-trial visit
Study NCT01140282 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: management of therapy complications
Description: Assessed within 3 days of baseline testing and at post-trial visit
Study NCT01140282 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise intervention
Description: 12 week exercise intervention
Study NCT04550559 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic ureterolitotripsy
Description: Endoscopic ureterolithotripsy
Study NCT04550559 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Endoscopic ureterolitotripsy
Description: Endoscopic ureterolithotripsy
Study NCT05080205 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Description: Roux-en-Y gastric bypass or sleeve gastrectomy, chosen based on routine evaluation process
Study NCT00621192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: meropenem
Description: Meropenem was administered concomitantly with compatible medications. Because an in-line filter is not appropriate due to drug binding, the 30 minute infusion was rate controlled by using appropriate infusion (syringe) pumps. Dosing and administration of other antimicrobial therapy (e.g., an aminoglycoside) was administered per local standard of care at the discretion of the infant's neonatologist. If there was a delay in the study drug shipment, sites were to use open-label meropenem to protect the safety of the participant.~20 mg/kg every 12 hours in infants \<32 weeks GA and PNA \< 2 weeks 20 mg/kg every 8 hours in infants \<32 weeks GA and PNA ≥ 2 weeks 20 mg/kg every 8 hours in infants ≥32 weeks GA and PNA \< 2 weeks 30 mg/kg every 8 hours in infants ≥32 weeks GA and PNA ≥ 2 weeks
Study NCT02754193 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: moderate hypothermia
Description: moderate hypothermia will be induced using the heat controller of the VA-ECMO circuit. Temperature will be maintained between 33°C≤ T°C ≤34°C during 24 hours ± 1h followed by a progressive reheating (0.2±0.1°C/h) to reach 37 °C. Temperature at 37°C ± 0.3°C will be maintained during 48 hours ± 4h after having reached 37 °C.
Study NCT04444219 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Breakfast meals
Description: Fifteen volunteers will undergo a medical and dietary assessment and their health status will be evaluated through a complete blood count. Then, they will come after overnight fasting and will consume one of two breakfast meals, including 114g bread, 40g cheese and 15g dry mushrooms (meal 1) or 114g bread, 40g cheese and 200g tomatoes (meal 2). Blood samples will be obtained on timepoints 0h, 30min, 1h, 1,5h, 2h, 2,5h and 3h after breakfast intake. Two weeks later, the same volunteers will consume the other breakfast meal.
Study NCT03654768 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bosutinib
Description: Given PO
Study NCT03654768 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dasatinib
Description: Given PO
Study NCT03654768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Given PO
Study NCT03654768 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT04121767 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: oral warfarin once daily for 3 months according to prothrombin time
Study NCT03654768 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03654768 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nilotinib
Description: Given PO
Study NCT03654768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Description: Given PO
Study NCT03654768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Given PO
Study NCT03654768 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imatinib
Description: Given PO
Study NCT03654768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: Given PO
Study NCT03903497 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: NBI
Description: optical assessment of diminutive colorectal polyps by NBI mode using the WASP assessment
Study NCT02087215 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: boron gel
Description: application of a formulation gel: addition of borate as sodium penta boric acid pentahydrate 3% (w/v) and two different copolymer as pluronic block namely F68 2% (w/v) and f127 2% (w/v) to diabetic foot ulcers.
Study NCT02087215 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04692545 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Immunonutrition
Description: nutridrinks 3 times a day 5 days prior surgery plus maltodextrins the day of surgery
Study NCT00166881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel-Irinotecan
Description: Docetaxel-Irinotecan, weekly, days 1, 8, 15, repeated every 4 weeks
Study NCT02635386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide once weekly (EQW )
Description: 2 mg SC injection every 7 days
Study NCT02635386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin (DAPA)
Description: One pill (10 mg) by mouth daily (QD) in am
Study NCT02635386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EQW plus DAPA
Description: 2 mg SC injection every 7 days One pill (10 mg) by mouth QD in am
Study NCT02635386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin plus Glucophage (MET ER)
Description: DAPA/MET ER-5 mg /1000 mg - 1 pill by mouth in am with food for 4 weeks DAPA/MET ER-10 mg /2000 mg - 2 pills in am by mouth with food -final dose
Study NCT02635386 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phentermine /Topiramate (PHEN/ TPM) ER
Description: PHEN 3.75/TPM ER 23mg - 1 pill by mouth once daily in am for 2 weeks. After 2 weeks, PHEN 7.5mg/TPM ER 46mg- 1 pill by mouth once daily in am
Study NCT01776008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Akt Inhibitor MK2206
Description: Given PO
Study NCT01776008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: Given PO
Study NCT01776008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin Acetate
Description: Given SC
Study NCT01776008 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01776008 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neoadjuvant Therapy
Description: Given before standard-care surgery
Study NCT01776008 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT01776008 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo standard-care surgery
Study NCT01993641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pracinostat
Description: Histone deacetylase inhibitor (HDACi) Pracinostat is to be taken before HMA administration 3 times/week (e.g., Monday, Wednesday, and Friday) for 3 weeks, followed by 1 week of rest as a 28-day cycle. Pracinostat administration will be at the clinic on Day 1 of Cycles 1 and 2 and subject will self-administer at home on all other days
Study NCT01993641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: All patients will receive the dose and schedule of azacitadine to which they previously failed to respond. (e.g. 75 mg/m2 via subcutaneous (SC) injection or intravenous infusion if SC injections are intolerable; 7 days of each 28 day cycle, either Days 1-7, or Days 1-5, rest on Days 6-7, and azacitadine dosing on Days 8-9)
Study NCT01993641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: All patients will receive the dose and schedule of decitabine to which they previously failed to respond. Common 28 day treatment regimens include: 20 mg/m2 IV for either 5 or 10 days of each 28-day cycle, 10 mg/m2 given intravenously daily for first 10 days of each 28 day cycle, or 20 mg/m2 given subcutaneously daily for the first 5 days of each 28 day cycle.~The 6-week regimen utilizes a dose of 15 mg/m2 by continuous intravenous infusion over 3 hours repeated every 8 hours for 3 days repeated every 6 weeks.
Study NCT02175329 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CAD/CAM Veneering
Description: CAD/CAM fabricated zirconia bridge framework is veneered with CAD/CAM fabricated lithium disilicate ceramic veneer
Study NCT02175329 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Manually layered veneering
Study NCT03183479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fibrinogen Concentrate Human
Description: After start of surgery when all pedicle screws are placed, the patients in treatment group will receive fibrinogen concentrate 30mg kg-1. For safety concern, functional fibrinogen will be measured and the maximum fibrinogen concentrate administration for each individual shall not exceed 2g. Fibrinogen concentrate will be diluted in 100mL of sterile water and then be administered to patients.
Study NCT03183479 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: 100mL normal saline will be administered to patients in control group as placebo
Study NCT02282163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sulphur hexafluoride lipid-type A microspheres
Description: Ultrasound imaging contrast agent
Study NCT04302129 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector spinae plane block
Description: 20 ml local anaesthetic are injected bilaterally on each side of the surgical incision underneath the erector spinae muscle where the dorsal rami pass around the bases of the transverse processes.
Study NCT04302129 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Multimodal analgesia
Description: Ketorolac 0.75 mg/ Kg and paracetamol 10 mg/ Kg intravenously
Study NCT01971281 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NovoTTF-100L
Description: Patients will be treated continuously with the NovoTTF-100L. TTFields treatment will consist of wearing four electrically insulated electrode arrays on the torso. The treatment enables the patient to maintain regular daily routine.
Study NCT01971281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m\^2 over 30 minute infusion will be administered once weekly for up to 7 weeks (or until toxicity necessitates reducing or holding a dose), followed by a week rest from treatment. Subsequent cycles will consist of once weekly infusions days 1, 8, 15 every 28 days.
Study NCT01971281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-Paclitaxel
Description: nab-paclitaxel 125 mg/m\^2 administered as an intravenous infusion over 30-40 minutes on days 1, 8 and 15 of each 28-day cycle.
Study NCT01711398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug
Study NCT01560195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated rhG-CSF: 100µg/kg
Description: Patients were administered pegylated rhG-CSF 100 ug/kg once at the 3rd day of every chemotherapy cycle. Chemotherapy regimen: docetaxel 75 mg/m2; carboplatin area under curve\[AUC\] 5 or cisplatin 75 mg/m2.
Study NCT01560195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated rhG-CSF: 6mg
Description: Patients were administered pegylated rhG-CSF 6mg once at the 3rd day of every chemotherapy cycle. Chemotherapy regimen: docetaxel 75 mg/m2; carboplatin area under curve\[AUC\] 5 or cisplatin 75 mg/m2.
Study NCT01560195 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo and rhG-CSF 5ug/kg/d
Description: Patients receiving chemotherapy and placebo in cycle 1 and rhG-CSF 5ug/kg/d in cycle 2 to 4. Chemotherapy regimen: docetaxel 75 mg/m2; carboplatin area under curve\[AUC\] 5 or cisplatin 75 mg/m2.
Study NCT01699308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genotropin
Study NCT00312052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E5555
Description: 50 mg or 100 mg E5555 tablets
Study NCT00312052 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: E5555
Description: 50 mg or 100 mg E5555 tablets
Study NCT00312052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 50 mg and/or 100 mg placebo tablets
Study NCT00312052 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 50 mg and/or 100 mg placebo tablets
Study NCT00745498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Patients will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml)